GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Return-on-Tangible-Equity

Vivos (RDGL) Return-on-Tangible-Equity : -235.80% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Vivos Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vivos's annualized net income for the quarter that ended in Sep. 2024 was $-3.30 Mil. Vivos's average shareholder tangible equity for the quarter that ended in Sep. 2024 was $1.40 Mil. Therefore, Vivos's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was -235.80%.

The historical rank and industry rank for Vivos's Return-on-Tangible-Equity or its related term are showing as below:

RDGL' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -337.29   Med: -191.34   Max: -157.93
Current: -213.75

During the past 13 years, Vivos's highest Return-on-Tangible-Equity was -157.93%. The lowest was -337.29%. And the median was -191.34%.

RDGL's Return-on-Tangible-Equity is ranked worse than
92.73% of 757 companies
in the Medical Devices & Instruments industry
Industry Median: 2.02 vs RDGL: -213.75

Vivos Return-on-Tangible-Equity Historical Data

The historical data trend for Vivos's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Return-on-Tangible-Equity Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -337.29 -157.93 -191.34

Vivos Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -170.41 -304.82 -167.30 -138.23 -235.80

Competitive Comparison of Vivos's Return-on-Tangible-Equity

For the Medical Devices subindustry, Vivos's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Vivos's Return-on-Tangible-Equity falls into.



Vivos Return-on-Tangible-Equity Calculation

Vivos's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-2.895/( (1.661+1.365 )/ 2 )
=-2.895/1.513
=-191.34 %

Vivos's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-3.3/( (1.603+1.196)/ 2 )
=-3.3/1.3995
=-235.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Vivos  (OTCPK:RDGL) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Vivos Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Vivos's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos Headlines

From GuruFocus

Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment

By Stock market mentor Stock market mentor 01-03-2023

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

By GuruFocusNews GuruFocusNews 01-24-2022

Vivos Inc. Enhances its Intellectual Property Protection

By GuruFocusNews GuruFocusNews 02-24-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 07-01-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-11-2022

Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy

By Stock market mentor Stock market mentor 01-11-2023

Vivos Inc Implements Multiple Patient IsoPet� Therapy Day

By GuruFocusNews GuruFocusNews 04-21-2022